Consistently, the results of a recent meta-analysis showing that dual RAS blockade with ACE inhibition and ARB is the most effective strategy to prevent end-stage renal disease in patients with diabetes and kidney disease [81]. The gene discussed is ACE; the disease is stage 5 chronic kidney disease.